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Abstract
Background: Hereditary angioedema (HAE) due to C1 inhibitor deficiency
manifests as recurrent swelling attacks that can be disabling and sometimes fatal.
Long-term prophylaxis with twice-weekly intravenous injections of plasma-derived
C1-inhibitor (pdC1-INH) has been established as an effective treatment. Subcutane-
ous (SC) administration of pdC1-INH has not been studied in patients with HAE.
Methods: This open-label, dose-ranging, crossover study (COMPACT Phase II) was
conducted in 18 patients with type I or II HAE who received two of twice-weekly 1500,
3000, or 6000 IU SC doses of highly concentrated volume-reduced CSL830 for 4 weeks
each. The mean trough plasma levels of C1-INH functional activity, C1-INH and C4
antigen levels during Week 4, and overall safety and tolerability were evaluated. The
primary outcome was model-derived steady-state trough C1-INH functional activity.
Results: After SC CSL830 administration, a dose-dependent increase in trough func-
tional C1-INH activity was observed. C1-INH and C4 levels both increased. The
two highest dose groups (3000 and 6000 IU) achieved constant C1-INH activity lev-
els above 40% values, a threshold that was assumed to provide clinical protection
against angioedema attacks. Compared with intravenous injection, pdC1-INH SC
injection with CSL830 showed a lower peak-to-trough ratio and more consistent
exposures. All doses were well tolerated. Mild-to-moderate local site reactions were
noted with pain and swelling being the most common adverse event.
Conclusions: Subcutaneous volume-reduced CSL830 was well tolerated and led to
a dose-dependent increase in physiologically relevant functional C1-INH plasma
levels. A clinical outcome study of SC CSL830 in patients with HAE warrants
further investigation.
Abbreviations
AE, adverse event; AUC(0t), area under the plasma concentration–time curve over a dosing interval; C1-INH, C1-inhibitor; Cav, average C1-
INH functional activity over dosing interval; CI, confidence interval; CL, clearance; CLSS, steady-state clearance; Cmax, maximum drug
concentration in plasma; CSL830, volume-reduced C1-INH concentrate; F, bioavailability; HAE, hereditary angioedema due to C1 inhibitor
deficiency; IU, international unit; IV, intravenous; Ka, absorption rate constant; kDa, kiloDalton; pd, plasma-derived; PD, pharmacodynamic;
PK, pharmacokinetic; pnf, pasteurized, nanofiltered; SC, subcutaneous; SD, standard deviation; t1/2, half-life; TEAE, treatment-emergent
adverse event; U, unit; V, volume of distribution; VSS, steady-state volume of distribution; WT, body weight.
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Allergy
Hereditary angioedema (HAE) is a rare autosomal dominant
disease caused by C1 inhibitor deficiency and is associated
with significant morbidity and mortality (1–4), which has been
substantially reduced with the advent of effective on-demand
therapies (5). However, patients continue to have impaired
quality of life and in some cases require hospitalization for an-
gioedema attacks. To minimize the number and severity of
attacks, many patients choose to use prophylactic treatment.
Consensus guidelines conclude that long-term prophylaxis is
appropriate for HAE patients with frequent attacks or who do
not achieve sufficient benefit from on-demand treatment (4, 6–
11). Before 2009, the most commonly utilized prophylactic drugs
were anabolic androgens and to a lesser extent antifibrinolytics.
Subsequently, long-term prophylaxis with C1 inhibitor concen-
trates (C1-INH) has become available and found to be safe and
effective (12). The concept of routine prophylaxis with continu-
ous intravenous C1-INH is based on correcting the deficiency of
C1-INH activity, the fundamental abnormality in HAE. The
efficacy of this approach was shown in two placebo-controlled
studies; the efficacy of a vapor-heated C1-INH concentrate
(25 U/kg body weight) was established for long-term prophy-
laxis in patients who did not respond adequately to androgens
or antifibrinolytics (13), and the C1-INH concentrate (Cinryze,
1000 IU twice a week) demonstrated a reduction in the number
of HAE attacks (12). However, none of the previous studies on
C1-INH replacement therapy were specifically designed to
achieve a constant level of biologically relevant activity C1-INH
levels. Thus, most patients on intravenous C1-INH long-term
prophylaxis continue to experience breakthrough attacks, likely
related to the relatively short period of time that functional
C1-INH plasma levels remain near the normal range (13).
Theoretically, maintaining plasma C1-INH functional levels
above a certain threshold should prevent all attacks. However,
this threshold value has not yet been defined. Hereditary angioe-
dema is diagnosed based on functional C1-INH levels <50% of
normal, but patients typically have C1-INH functional levels
<40% of normal (14, 15). Enhanced activation of the complement
system has been observed with C1-INH functional levels <38%
of normal, suggesting a critical threshold of C1-INH function
(16). Logistical and technical problems of repeated intravenous
(IV) injections and the pharmacokinetic (PK) profile make it chal-
lenging to maintain the C1-INH level above a threshold value.
Subcutaneous (SC) administration of C1-INH offers sev-
eral potential advantages including easier access for self-
administration and more consistent PKs. The feasibility of
SC administration of an IV C1-INH concentrate (1000 IU in
20 ml) was previously demonstrated in a pilot study in
patients with HAE (17). Herein, the PK, pharmacodynamic
(PD), and preliminary safety of an investigational, volume-
reduced C1-INH concentrate (CSL830; CSL Behring, Mar-
burg, Germany) developed for SC injection is reported.
Methods
Study medication
CSL830 is a volume-reduced formulation of the pasteurized,
nanofiltered C1-INH concentrate (pnf C1-INH; Berinert,
Marburg, Germany). The manufacturing process of CSL830
is almost identical to that of pnf C1-INH, the major differ-
ence being the concentration after reconstitution. The final
concentration of CSL830 is 500 IU/ml, whereas the final con-
centration of Berinert is 50 IU/ml.
Study design
This was a prospective, multicenter, open-label, crossover
phase II study to characterize the PKs, PDs, and safety of
CSL830 administered subcutaneously to 18 subjects with
HAE (COMPACT phase II study). The study period spanned
April 2012 to December 2012. Data were collected at three
sites in Germany and five in the USA. For organizational
details of the study setup, please refer to the Appendix S1.
Following a screening period of up to 30 days, subjects
were sequentially allocated to one of six CSL830 treatment
sequences by predetermined computer-generated assignment
(Fig. 1A). A single dose of Berinert 20 U/kg was adminis-
tered IV 2–7 days prior to the first CSL830 dosing period.
Each subject received two of three possible CSL830 doses
(1500, 3000, or 6000 IU administered as a short SC injection
twice-weekly) for two 4-week treatment periods with a wash-
out period of up to 4 weeks between periods. Administration
of rescue medication (IV C1-INH) was permitted for break-
through attacks.
The study protocol and all amendments were approved by
the independent ethics committees of the participating sites.
The study was carried out in accordance with the principles
of the current International Conference on Harmonization
Good Clinical Practice.
Study population
Male or female subjects aged ≥18 with HAE with type I or
type II HAE, based on clinical history and confirmed by cen-
tral laboratory testing at screening (C1-INH functional activ-
ity <50% or a C1-INH antigen level below the laboratory
reference range), were eligible for the study. Subjects were
required to have a body weight ≥50 and ≤110 kg at screening
and have experienced ≤5 HAE attacks within the 3 months
prior to the screening visit, of which ≤1 occurred within
30 days prior to the screening visit. The relatively low attack
rate for the inclusion criteria was chosen to minimize the
need for rescue therapy with C1-INH concentrate which
would interfere with the PK measurements.
Key exclusion criteria included current C1-INH prophylac-
tic therapy, androgen therapy within 30 days of screening,
and any HAE-specific treatment within 7 days of screening
(for full inclusion and exclusion criteria, see Appendix S1).
Endpoints
The primary endpoint was the mean trough C1-INH func-
tional activity at the fourth week, based on modeling and
simulation. Model-derived rather than observed trough levels
were chosen to account for the confounding nature of possi-
ble rescue IV C1-INH use during the study.
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The secondary endpoints were the mean and mean change
from baseline in trough C1-INH functional activity, C1-INH
antigen level, and C4 antigen levels at the fourth week of
each dosing regimen, based on observed data.
The dosing scheme and sample collection is illustrated in
Fig. 1B. The initial single IV dose of C1-INH was adminis-
tered to aid the PK model in accounting for any administra-
tion of IV C1-INH rescue doses and to enable a within-study
estimate of bioavailability of SC CSL830. C1-INH functional
activity, C1-INH plasma concentrations, and C4 antigen lev-
els were assessed at several time points throughout each dos-
ing period. Plasma C1-INH functional activity was
additionally assessed immediately before CSL830 administra-
tion.
PK and PD measurements
Plasma C1-INH functional activity was assessed by a vali-
dated chromogenic assay (Berichrom C1-Inhibitor, Siemens;
reference range: 70–130% of norm). Plasma C1-INH antigen
(C1 reagent N-Antisera; Siemens Healthcare Diagnostics
(Eschbom, Germany); reference range: 0.18–0.32 mg/l) and
C4 antigen levels were assessed by nephelometry (C4 reagent,
Beckman Coulter (Krefeld, Germany); reference range: 0.1–
0.4 g/l). All measurements were performed at a central labo-
ratory using a validated assay (CSL Behring GmbH).
C4 antigen levels were defined as a PD parameter as C4
activity occurs downstream from C1-INH; C1-INH replace-
ment would therefore affect C4 levels. Levels of C4 antigen
have been shown to rise slowly over time following IV pdC1-
INH administration.
PK and PD analysis
The complete analysis set (18 patients who received ≥1 dose
of CSL830 and provided ≥1 C1-INH functional measure-
ment) was used for the primary endpoint analysis and to
determine modeling-derived C1-INH functional activity.
A
B
Figure 1 Study schema. (A) Dosing scheme and sample collection
during the study, (B) = single dose of IV C1-INH; = single dose
of subcutaneous (SC) CSL830; = assessment of C1-INH func-
tional activity and plasma C1-INH and C4 antigen concentrations;
= additional assessments of plasma C1-INH functional activity.
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Twelve subjects per dosing regimen were sufficient to provide
an estimate of C1-INH activity, based on PK modeling of
previous study results. The data for each treatment were
summarized using descriptive statistics and a mixed model.
Subcutaneous and IV C1-INH functional activity data
were collectively subjected to a population-based approach
using nonlinear mixed-effects modeling (NONMEM version
7.2). Exploratory PK characteristics of CSL830 were assessed
by estimating typical and individual values for parameters
such as clearance (CL) and volume of distribution (V) along
with associated interindividual variability. The influence of
subject baseline characteristics was also investigated. Pharma-
cokinetic parameters such as CL, V, bioavailability (F),
absorption rate constant (Ka), half-life (t1/2), and incremental
recovery were estimated with the final population PK model.
Pharmacokinetic simulations were conducted to examine
whether steady-state trough levels of C1-INH functional
activity were dependent on body weight. The body weight
effect was evaluated by examining the distributions of model-
predicted steady-state trough serum C1-INH functional activ-
ity at doses of 40 and 60 IU/kg and fixed doses of 3000 and
4500 IU, for baseline body weight ranges of <60, 60–100,
and >100 kg. For the as-observed endpoint analysis, the
fourth-week trough levels and increase in trough levels from
baseline were summarized for C1-INH functional activity,
C1-INH antigen levels, and C4 antigen levels for each
CSL830 dosing regimen using descriptive statistics.
Safety assessment
Safety and tolerability were evaluated by continuous observa-
tion of adverse events (AEs) and by safety assessments that
were conducted at specified times throughout the study.
These assessments included infusion site tolerability, labora-
tory parameters, vital signs, body weight, physical examina-
tion, and concomitant medication usage. Local side-effects
(pain, swelling, bruising, and itching at the injection site)
were assessed by the investigator and intensity graded from
mild (grade 1: present, but no interference with activity) to
severe (grade 3: prevents daily activity and/or requires use of
pain relievers). A risk assessment for deep vein thrombosis
was also implemented based on earlier case reports on side-
effects of thromboembolism in patients with HAE using
C1-INH concentrate (18, 19).
Results
Study subjects
A total of 22 subjects from eight study sites signed the
informed consent. Of these, 18 patients were assigned to
treatment by a computer-generated list and received study
drug. Four subjects signed the consent form but were not
randomized, two because they did not meet the inclusion/
exclusion criteria and two because the study had already
reached the target of 18 subjects by the time they were found
to be eligible. The demographics of the subjects are summa-
rized in Table 1.
PK results after SC CSL830
The mean as-observed steady-state trough C1-INH functional
activity at the fourth week increased with CSL830 dose
(Fig. 2); increase from baseline was 16.4%, 33.2%, and
63.3% for the 1500, 3000, and 6000 IU doses, respectively.
C1-INH antigen levels also increased with CSL830 dose;
increase from baseline in C1-INH antigen at the fourth week
was 0.02, 0.05, and 0.14 mg/ml for the three dosing regimens,
respectively.
Population PK model
C1-INH functional activity was described by a linear one-
compartmental PK model with first-order absorption. The
relationships between model parameters and the following
baseline covariates were examined: age, gender, body weight,
body mass index, ideal body weight, lean body mass, creati-
nine CL, and C1-INH functional activity. The only statisti-
cally significant covariate effect on a model parameter
identified was the effect of body weight on CL and V, which
was described by the following relationships:
CLi ¼ 0:398  WTiðkgÞ
78:9ðkgÞ
 0:879
 expgCL ;
Vi ¼ 30:8  WTiðkgÞ
78:9ðkgÞ
 0:669
 expgV ;
where CLi is the individual value of clearance; Vi, the indi-
vidual volume of distribution; and WTi, the body weight of
subject i.
Goodness-of-fit plots of the model (Fig. 3) reveal that the
model prediction was consistent with the observed data, as
the points are uniformly distributed around the line of iden-
tity. Therefore, no systematic bias was evident.
Model-derived C1-INH trough levels and PK parameters
The primary endpoint was the mean trough C1-INH func-
tional level at the fourth week, based on modeling and simu-
lation (Fig. 2). A dose-dependent increase in mean C1-INH
functional activity was observed, increasing from 14.6% at
baseline to 31.7%, 44.3%, and 80.5% for the 1500, 3000,
and 6000 IU doses, respectively. The modeled steady-state
trough C1-INH functional activity at the fourth week was
similar to the as-observed C1-INH functional activity.
The model was also used to derive other exploratory PK
parameters such as area under the activity–time curve from
zero to end of dosing interval at steady state (AUC(0t)),
maximum plasma C1-INH functional activity levels (Cmax),
average plasma activity at steady state (Cavg), incremental
recovery, and elimination half-life. Table 2 summarizes the
modeled PK parameters for functional C1-INH activity fol-
lowing IV and SC C1-INH administration. The bioavailabil-
ity of SC CSL830 was 44%, with similar elimination half-life
compared with IV C1-INH. As the CSL830 doses used were
not weight based, body weight, body mass index, and ideal
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Table 1 Demographic and baseline characteristics (complete analysis set)
Demographic characteristics
Dosing regimen
Berinert (N = 18)
CSL830
1500 IU (N = 12)
CSL830
3000 IU (N = 12)
CSL830
6000 IU (N = 12)
Age, years
Mean (SD) 36.4 (13.07) 33.6 (11.83) 37.8 (14.69) 37.8 (12.65)
Median (min, max) 33.9 (19, 69) 30.3 (19, 53) 36.9 (19, 69) 35.2 (24, 69)
Sex, male : female, n (%) 7 : 11 (38.9 : 61.1) 4 : 8 (33.3 : 67.7) 5 : 7 (41.7 : 58.3) 5 : 7 (41.7 : 58.3)
Weight, kg
Mean (SD) 80.0 (20.2) 79.9 (23.4) 78.5 (17.0) 81.6 (20.6)
Median (min, max) 78.9 (51.0, 110.0) 71.2 (51.0, 110.0) 78.9 (57.6, 106.5) 83.3 (51.0, 110.0)
Body mass index, kg/m2
Mean (SD) 27.3 (6.57) 27.5 (7.22) 26.8 (5.14) 27.6 (7.37)
Median (min, max) 25.4 (18.1, 40.9) 25.4 (18.1, 40.9) 25.4 (19.1, 34.5) 27.5 (18.1, 40.9)
HAE type, n (%)
Type I 16 (88.9) 12 (100) 10 (83.3) 10 (83.3)
Type II 2 (11.1) 0 (0) 2 (16.7) 2 (16.7)
Number of HAE attacks in the preceding 3 months, n
Mean (SD) 2.5 (1.42) 2.3 (1.50) 2.4 (1.51) 2.8 (1.29)
Median (min, max) 2.0 (0, 5) 2.0 (0, 5) 2.0 (0, 5) 2.0 (1, 5)
Baseline as-observed C1-INH functional activity, %
Mean (SD) 14.6 (8.02) 15.4 (8.02) 11.3 (7.10) 17.1 (8.05)
Median (min, max) 15.2 (1.3, 26.7) 15.2 (4.3, 26.7) 9.9 (1.3, 22.7) 19.3 (1.3, 26.7)
Baseline as-observed C1 antigen level (mg/ml)*
n 13 8 9 9
Mean (SD) 0.10 (0.126) 0.05 (0.009) 0.12 (0.149) 0.12 (0.147)
Median (min, max) 0.050 (0.02, 0.44) 0.047 (0.03, 0.05) 0.050 (0.02, 0.44) 0.053 (0.02, 0.44)
Baseline as-observed C4 antigen level (mg/dl)*
n 17 12 11 11
Mean (SD) 8.6 (9.51) 6.8 (3.10) 9.2 (11.7) 9.9 (11.7)
Median (min, max) 7.0 (2.2, 43.8) 6.9 (2.2, 10.8) 7.0 (2.2, 43.8) 7.0 (2.4, 43.8)
HAE, hereditary angioedema.
*In some patients, the values for baseline as-observed C1 and C4 antigen were below the limits of detection of 0.022 mg/ml and
1.67 mg/dl, respectively. Complete analysis set: 18 patients who received ≥1 dose of CSL830 and provided ≥1 C1-INH functional
measurement.
Figure 2 Pharmacokinetic (PK) results. Modeled steady-state
trough C1-INH functional activity (primary endpoint; red rectangles)
and as-observed C1-INH functional activity (black triangles). Data
points show the mean and 95% CI.
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Figure 3 Final population pharmacokinetic (PK) model of as-observed
C1-INH functional activity vs individual predictions of C1-INH func-
tional activity. The line of identity (solid red) is included as a reference.
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body weight were assessed to determine their influence on
median functional C1-INH levels. Not unexpectedly, we
found a small negative relationship between body weight and
steady-state trough levels for each dose regimen. Patients
with a low body weight administered a fixed dose are pre-
dicted to achieve a relatively high functional C1-INH level
compared with patients with a higher body weight. There-
fore, a body weight-adjusted dosing is predicted to achieve
the same level of activity across the range of body weights
(see Fig. S1).
Pharmacodynamics
C4 antigen levels were also measured during the fourth week
of each dose regimen. C4 antigen levels increased in a dose-
dependent manner and normalized with all doses of CSL830.
C4 levels of 11.1, 14.1, and 18.4 mg/dl for the 1500, 3000,
and 6000 IU doses of CSL830, respectively, were observed.
C4 antigen levels increased from baseline at the fourth week
by 4.3, 5.6, and 9.1 mg/dl (normal level is 14 mg/dl) for the
1500, 3000, and 6000 IU doses, respectively.
When the fixed dose of CSL830 was calculated as a dose
per body weight, the mean C4 antigen level increased with
the dose per body weight; the mean as-observed C4 antigen
level at the fourth week was 11.3, 11.7, 18.0, and 18.2 mg/ml
in the ≤20, >20 to ≤45, >45 to ≤90, and >90 IU/kg categories,
respectively.
Modeled twice-per-week CSL830 vs IV pdC1-INH over
4 weeks
The effect of dosing SC CSL830 vs IV 1000 IU pdC1-INH
concentrate on C1-INH functional activity was examined in
a post hoc analysis by simulating three different SC regimens
of 1500, 3000, and 6000 IU twice-weekly for 4 weeks
(Fig. 4). The simulated C1-INH functional activity time pro-
files showed a lower peak-to-trough ratio and more consis-
tent exposures after SC administration compared with the
current standard prophylactic treatment regimen of a twice-
weekly injection of 1000 IU pdC1-INH concentrate.
Safety
There were no CSL830-related serious AEs or deaths, or
withdrawals due to AEs throughout the study. No thrombo-
embolic events were observed. Two serious AEs unrelated to
CSL830 were reported, an episode of transient syncope
2 days after IV pdC1-INH administration in a 23-year-old
woman and hypovolemic shock in a 27-year-old woman on
the first dosing day of CSL830 during an abdominal attack
that started before study drug administration. Laboratory
surveillance did not reveal any safety signals, and there was
no evidence of inhibitory auto-antibody development.
Adverse events are summarized in Table 3. The most com-
mon treatment-emergent adverse events were local site reac-
tions reported as pain, swelling, bruising, and itching at the
injection sites.
Most local site reactions were mild-to-moderate in intensity
and resolved within 3 days. Moderate swellings at the injection
site was reported in more subjects in the 6000 IU dose group
(5/12 subjects) compared with the two other lower dose groups
(2/12 in the 1500 IU and 1/12 in the 3000 IU dose group),
which were likely related to the volume of injection. There was
no apparent dose relationship for other local site reactions.
Hereditary angioedema-related symptoms occurring during
the study were reported as AEs. Overall, 29 HAE-related
AEs were reported in seven patients during the course of the
study. Of those 29 HAE events occurring after study enroll-
ment, 11 were reported during the 4-week dosing intervals
with SC CSL830 and 18 HAE events were reported during
times in the study with no exposure to the investigational
drug. In the 1500 IU dose group, two of 12 patients had two
and five HAE attacks, respectively. In the 3000 IU dose
group, two patients had one and three attacks, respectively.
No patient in the 6000 IU dose group experienced any HAE
symptoms during the 4-week SC dosing period.
Table 2 Modeled pharmacokinetic parameters for C1-INH activity
Berinert 20 IU/kg
(N = 18)
CSL830
1500 IU (N = 12)
CSL830
3000 IU (N = 12)
CSL830
6000 IU (N = 12)
Cmax, U/ml 0.67 (0.562) 0.38 (0.109) 0.59 (0.154) 1.09 (0.307)
AUC(0t), U h/ml 38.9 (8.93) 30.5 (11.31) 45.3 (11.98) 79.6 (25.36)
Cav, U/ml – 0.36 (0.135) 0.54 (0.142) 0.95 (0.303)
Incremental recovery ([U/ml]/[U/kg]) 0.026 (0.0023) 0.011 (0.0024) 0.011 (0.0024) 0.012 (0.0027)
t1/2 (h) 52.8 (13.70) 50.6 (12.35) 51.5 (13.52) 56.2 (15.02)
Dose independent (n = 18)
CLSS, l/h 0.043 (0.015)
VSS, l 3.06 (0.598)
Bioavailability 0.44
AUC(0t), area under the plasma concentration–time curve over a dosing interval; Cav, average C1-INH functional activity over a dosing inter-
val; t1/2, elimination half-life; Cmax, maximum drug concentration in plasma; CLSS, steady-state clearance; VSS, steady-state volume of distri-
bution.
Data are mean (SD).
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Discussion
Long-term prophylaxis of HAE aims to prevent or minimize
the number and severity of angioedema attacks; however, the
medications currently available for long-term prophylaxis are
in many cases suboptimal. Oral antifibrinolytics requiring
multiple daily doses are relatively ineffective and frequently
associated with significant side-effects (20, 21). Anabolic
androgens are convenient to take and often effective at doses
<200 mg/day but can be associated with significant risk of
A B
C D
Figure 4 Modeled biweekly C1-INH functional activity after IV
administration of (A) a therapeutic dose of 1000 IU pdC1-INH con-
centrate, or subcutaneous (SC) administration of (B) 1500 IU, (C)
3000 IU, or (D) 6000 IU of CSL830. Median functional activity (solid
lines), 5th and 95th percentiles (shaded areas) and 40% C1-INH
functional activity (dashed black line) are shown.
Table 3 Treatment-emergent adverse events (TEAEs) by dose group
Dosing regimen
All treated
subjects (N = 18)
CSL830
1500 IU (N = 12)
CSL830
3000 IU (N = 12)
CSL830
6000 IU (N = 12)
Subjects who reported any CSL830 TEAE, n (%) 17 (94.4) 10 (83.3) 8 (66.7) 9 (75.0)
Maximum reported event intensity of severe, n (%) 5 (27.8) 3 (25.0) 1 (8.3) 1 (8.3)
Maximum reported event intensity of moderate, n (%) 8 (44.4) 5 (41.7) 4 (33.3) 5 (41.7)
Assessed by investigator as related to CSL830, n (%) 6 (33.3) 5 (41.7) 1 (8.3) 2 (16.7)
Subjects with solicited local site reactions, n (%) 17 (94.4) 11 (91.7) 8 (66.7) 11 (91.7)
Pain 14 (82.4) 9 (72.7) 8 (100.0) 7 (63.6)
Swelling 14 (82.4) 8 (72.7) 7 (87.5) 9 (81.8)
Bruising 7 (41.2) 5 (45.5) 1 (12.5) 4 (36.4)
Itching 2 (11.8) 2 (18.2) 0 (0.0) 0 (0.0)
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serious side-effects (22–25). Currently available formulations
of pdC1-INH require IV access, imposing a burden on the
patient or healthcare provider. Maintenance of IV access has
required many patients to have ports implanted, which are
associated with increased risks of infection and thrombosis
(18, 19). Plasma levels of functional C1-INH fall rapidly fol-
lowing IV administration of therapeutic dosages of C1-INH
concentrates, reaching near basal levels within 3 days (13).
The failure to achieve therapeutic steady-state functional C1-
INH levels during pdC1-INH prophylaxis may explain the
occurrence of breakthrough attacks for many patients.
Replacement of pdC1-INH subcutaneously may potentially
address the above limitations.
Based on earlier observations, it was suggested (16) that
C1-INH antigen levels above 0.075 g/l, approximately 40%
of the plasma level in a healthy person, would have a clini-
cally meaningful effect in preventing HAE attacks. The C1-
INH concentrations below 0.075 g/l found in blood samples
analyzed after an attack and the increase in frequency of
attacks when C1-INH levels were below 0.035 g/l (18% of
normal) support this suggestion.
Our study demonstrates that SC CSL830 administered
twice-weekly for 4 weeks leads to a dose-dependent increase
in functional C1-INH activity and C4 levels, with the 3000
and 6000 IU doses achieving constant C1-INH activity levels
above 40%. C1-INH functional levels approached the range
of normal C1-INH values of healthy subjects with the
6000 IU dose.
Compared with a standard IV prophylactic dose regimen
of 1000 IU twice-weekly, our PK model predicted C1-INH
functional activity time profiles with a considerably lower
peak-to-trough ratio and more consistent exposures after SC
administration. The lower peak-to-trough fluctuations are the
expected consequence of SC dosing.
The size of a protein transported within the body, whether
via the capillaries or lymphatics, affects its bioavailability.
The 105 kDa C1-INH protein is taken up by the lymphatics
(26, 27). The 44% bioavailability of SC CSL830 was similar
to that observed in a pilot study using the IV pdC1-INH
concentrate, Berinert (17). Reasons for the relatively low bio-
availability could be attributed, in part, to degradation or
consumption at the injection site or during lymphatic trans-
port. It is known that C1-INH can be metabolized quickly in
patients with C1-INH deficiency, as evidenced by reduced
serum concentrations of 5–31% in patients with type I HAE;
this is in contrast to most other inherited plasma protein defi-
ciencies in which heterozygous carries have 50% of normal
protein levels (27, 28). In addition, the half-life of exogenous
C1-INH has been shown to be influenced by the severity of
HAE as well as by whether the assessment was made in
patients during an attack or not (17).
Overall, CSL830 was well tolerated, with no serious drug-
related AEs. The most common AEs were mild-to-moderate
local site reactions. Although this study was not designed to
test efficacy, a trend of fewer HAE attacks occurring with
the 3000 and 6000 IU doses was observed compared with the
1500 IU dose and the treatment-free period. A placebo-con-
trolled study would be required to ascertain whether this
effect was significant; however, the possibility that an efficacy
signal in this preliminary study was observed is encouraging.
In conclusion, C1-INH replacement through repeated SC
dosing of a volume-reduced C1-INH concentrate (CSL830)
led to a predictable dose-dependent increase in functional
C1-INH levels in patients with mild-to-moderate HAE. Fur-
thermore, consistent and sustained steady-state C1-INH lev-
els reached values that are predicted to be efficacious in
preventing angioedema attacks. Subcutaneous CSL830 also
appears to be safe and well tolerated. These results support
the pursuit of studies to address the safety and efficacy of SC
C1-INH for long-term prophylaxis in HAE patients with
severe disease.
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